// App-Quantinova.ai

202 : Risk Factors Associated with Serious Infections Among Users of Biosimilar and Originator Infliximab Therapies

Researchers

Presenter

  • Cristiano S. Moura

Principal Investigators

  • Jeffrey Curtis

  • Denis Choquette

  • Gilles Boire

  • Vivian P. Bykerk

  • Carter Thorne

  • Walter P. Maksymowych

  • Peter L. Lakatos

  • Larry Svenson

  • Laura Targownik

  • Waqqas Afif

Medical Centers

  • McGill University Health Centre, Montreal, QC, Canada

  • University of Alabama at Birmingham, Birmingham, AL

  • Institut de Recherche en Rhumatologie de Montréal, University of Montreal, Québec, Canada., Montreal, QC, Canada

  • Sherbrooke University, Sherbrooke, Quebec, Canada

  • Hospital for Special Surgery, New York, NY.

  • Stronach Regional Cancer Centre, Newmarket, ON, Canada

  • University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada

  • Montreal University, Montreal, QC, Canada

  • University of Alberta, Edmonton, AB, Canada

  • Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada

  • Research Institute McGill University Health Center, Montreal, Quebec, Canada

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

  • Autoimmune (AI)

  • Gastroenterology (GU)

Disease

  • Ankylosing spondylitis

  • Rheumatoid arthritis

  • Psoriatic arthritis

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • Infliximab Biosimilar

  • Glucocorticoid

  • Infliximab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved